The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Promising investigational CAR-T approaches for myeloma: dual-targeted CAR-T products
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on the promising investigational CAR T-cell therapy approaches for multiple myeloma (MM), namely dual-targeted CAR-Ts, which could help overcome the limitations of current monotherapy CAR-T products. Dr Hansen highlights that, so far, results with these approaches have been encouraging and may offer improved efficacy and reduced toxicities. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We still have not only dual-targeted CARs, but we have some other exciting CARs and some data we’ve presented at ASH, particularly with anito-cel, which is still a BCMA-directed CAR T-cell product. The results are quite promising, and we don’t see these delayed neurologic toxicities that we’ve seen with the other BCMA products, particularly cilta-cel...
We still have not only dual-targeted CARs, but we have some other exciting CARs and some data we’ve presented at ASH, particularly with anito-cel, which is still a BCMA-directed CAR T-cell product. The results are quite promising, and we don’t see these delayed neurologic toxicities that we’ve seen with the other BCMA products, particularly cilta-cel. But then you’re right – what I’m really excited about is the dual-targeted approaches. We have CD19 and BCMA. We have GPRC5D as well as BCMA and actually the PI is at our site for that dual-targeted CAR. The results look very encouraging, and we hope that if you do develop resistance to one target, hopefully you can overcome that by utilizing a second novel target, such as GPRC5D. And we’ve hopefully limited on-target off-tumor toxicities that are easier to resolve than some of the, for example, talquetamab-based toxicities. So very exciting future in terms of these dual-targeted CARs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research funding: Bristol Myers Squibb/Celgene, Janssen, Adaptive Biotechnologies, Kite Pharma, Karyopharm; Additional funding from Pentecost Myeloma Research Center, Myers Foundation, Schulze and M-CARES awards (pilot grants) via Moffitt Cancer Center; Consultancy: Bristol Myers Squibb, Janssen, Legend Biotech, Karyopharm, Kite Pharma, AstraZeneca, Pfizer.
